<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-28T01:55:05Z</responseDate><request verb="GetRecord" identifier="oai:kostu-rdlopen.rawdatalibrary.net:kostu/10860" metadataPrefix="oai_dc">https://kostu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:kostu-rdlopen.rawdatalibrary.net:kostu/10860</identifier><datestamp>2026-10-27T23:53:27Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_kostu_10000</setSpec><setSpec>col_kostu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>In silico biochemical de novo drug design of valproic acid  derivatives to suppress cancerous dna: comprehensive  molecular docking, molecular dynamics, 1 h nmr, adme</dc:title><dc:creator>Acar, Esra</dc:creator><dc:creator>Issa, Ghassan</dc:creator><dc:creator>Agar, Soykan</dc:creator><dc:creator>Gökoluk, Erkan</dc:creator><dc:creator>Giglou, Erfan Akhavan</dc:creator><dc:creator>Şimşek, Dilruba</dc:creator><dc:subject>Kimya, Tıbbi</dc:subject><dc:subject>Onkoloji</dc:subject><dc:subject>Biyokimya ve Moleküler Biyoloji</dc:subject><dc:subject>Farmakoloji ve Eczacılık</dc:subject><dc:description>Objective: This comprehensive in silico computational and theoretical  biochemistry/organic chemistry research study covers the inhibition  methodologies of 1-BNA, which is an essential template for cancer- suppressing research. By disrupting the minor groove domain binding  site of the DNA template 1-BNA dodecamer, three de novo drug  candidate molecules via derivatization of anti-epileptic valproic acid  (VPA) drug were designed. Methods: Calf thymus DNA (ct-DNA) sequence d(CGCGAATTCGCG)2 dodecamer (PDB ID: 1BNA) was obtained from the Protein Data Bank  to study. Molecular docking simulations, the most updated docking  programs of AutoDock Vina and PyRx were utilized. Molecular  dynamics (MD) simulations and Absorption, distribution, metabolism  and excretion (ADME) analyses were employed by Schrödinger’s  Desmond software. Results: Thorough in silico results of three new derivatized analogues  of VPA showed that chloro-derivatized analogue with its -9.6 kcal/mol  docking score and 297.2 µM inhibition constant (IC) has a much better  indication in the suppression where isopropyl and fluoro derivatized  analogues possess -9.1 kcal/mol docking score with 483.8 µM IC and - 8.3 kcal/mol docking score with 896.2 µM IC respectively compared to  the results of pristine VPA’s -8.2 kcal/mol docking score with 863.6 µM  IC. Along with the detailed ADME results, isopropyl and chloro- derivatized ligands prove their worth of being a new drug candidate. Conclusion: All results proved that the de novo derivatives of VPA  illustrate better docking scores (better suppression) along with better  ICs and oral absorption percentage values, meaning that the analogues  possess better indications compared to pristine VPA toward the  suppression of cancerous cell template DNA.</dc:description><dc:date>2026</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/kostu/10860</dc:identifier><dc:identifier>https://doi.org/10.53446/actamednicomedia.1814797</dc:identifier><dc:language>en</dc:language><dc:relation>Acta Medica Nicomedia</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://kostu-rdlopen.rawdatalibrary.net/tr/items/kostu/10860</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>